Gestational Diabetes Mellitus and Neurodevelopment in Newborns

Université de Sherbrooke46 enrolled

Overview

The purpose of this study is to evaluate the feasibility of using a quantitative EEG method to evaluate neurodevelopment in newborns and to evaluate whether subtle neurodevelopmental deficits can be detected in newborns from mothers with gestational diabetes mellitus (GDM) compared to control newborns. The second purpose of this study is to determine whether cord blood concentration in docosahexaenoic acid (DHA), an omega-3 fatty acid, is similar in neonates of well-controlled mothers with gestational diabetes mellitus (GDM) compared to control mothers, and to evaluate whether this contributes to neonates neurodevelopment status.

Maternal weight is measured close to delivery and BMI is calculated. Birth weight, length, head circumference, Apgar score and glycaemia are recorded at birth. An EEG are performed on the newborn within 48 hrs after birth.A maternal blood sample is collected at admission to measure maternal glycated hemoglobin (A1C). Cord blood samples are collected in the umbilical vein after delivery.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetes, Gestational Glucose Metabolism Disorders

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * singleton pregnancy * aged between 18 and 40 years Exclusion Criteria: * smoking, * illicit drug consumption, * omega-3/6 consumption, * liver or renal disease, * cancer * any medical conditions affecting glucose/lipid metabolism.

Outcomes

Primary Outcomes

Change in neurodevelopment

Evaluate change in neurodevelopment with GDM

Time frame: At birth

Secondary Outcomes

Change in DHA level in cord blood

Evaluate change in DHA level with GDM

Time frame: At birth